Sign in Subscribe
Medical research

Autoimmune Encephalitis: New Study Uncovers Key Diagnostic Insights

Strategic Insights

— 1 min read

A new study has shed light on autoimmune encephalitis, specifically focusing on G-Aminobutyric acid B receptor (GABAR)-IgG, an intermediate-risk paraneoplastic autoantibody often associated with seizures. Researchers at the University of Alberta have investigated the clinical and oncological features of GABAR-IgG autoimmune encephalitis and developed a novel diagnostic assay, live-cell flow cytometry-based assay (LCFBA). The study revealed that LCFBA performs very well as a diagnostic test with high sensitivity and specificity, improving the identification of true-positive patients.

Key Takeaways:

  • GABAR-IgG is an intermediate-risk paraneoplastic autoantibody associated with seizures in patients with autoimmune encephalitis.
  • The study assessed the clinical and oncological features of GABAR-IgG autoimmune encephalitis in 86 patients, with 55 presenting with encephalopathy and seizures, 23 with status epilepticus, and 8 with rapidly progressive dementia.
  • 44 patients (33%) had false-positive results for GABAR-IgG, characterized by non-specific symptoms and alternate diagnoses.
  • Malignancy was identified in 78% of true-positive patients, predominantly small cell lung carcinoma (SCLC).
  • The live-cell flow cytometry-based assay (LCFBA) improved the identification of true-positive patients, with a p-value of <0.01.
  • The study suggests that LCFBA is a valuable diagnostic tool for autoimmune encephalitis, with high sensitivity and specificity.

Statistics:

  • 86 patients were studied, with a median age of 63 years and 43 female patients.
  • 55 patients presented with encephalopathy and seizures, 23 with status epilepticus, and 8 with rapidly progressive dementia.
  • 44 patients had false-positive results for GABAR-IgG.
  • 78% of true-positive patients had malignancy, predominantly small cell lung carcinoma (SCLC).
  • The p-value for the improved identification of true-positive patients using LCFBA was <0.01.

Sources:

  • NewsRx. New Findings on Encephalitis Discussed by Researchers at University of Alberta (Anti-g-aminobutyric acid B receptor autoimmune encephalitis: Clinical presentation and diagnostic insights). Health & Medicine Week. October 17, 2025; p 3314.
  • Epilepsia (2025) - www.onlinelibrary.wiley.com/journal/10.1111/(ISSN)1528-1167
  • University of Alberta, Division of Neurology, Dept. of Medicine, Edmonton, Alberta, Canada.

Read more